FGF21 has substantial promise as a novel biomarker as its circulating level gives an insight into several pathophysiological processes, such as oxidative stress, cardiac hypertrophy, and inflammation, that are involved in HF [24, 25]. This evidence concerns the gene FGF21 and hydrops fetalis.